JAVELIN Renal 101: Combination Therapy vs Standard of Care in Advanced RCC

Leggi l'articolo originale


Research presented at ASCO GU 2019 compared PFS with avelumab and axitinib vs sunitinib in patients with advanced renal cell carcinoma.

Lascia un commento